0Z2 Stock Overview A clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Alector, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Alector Historical stock prices Current Share Price US$1.70 52 Week High US$7.70 52 Week Low US$1.70 Beta 0.51 1 Month Change -50.87% 3 Month Change -66.00% 1 Year Change -76.39% 3 Year Change -91.58% 5 Year Change -89.03% Change since IPO -88.48%
Recent News & Updates
Alector, Inc. Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’S Disease and Provides Business Update Nov 26 Alector, Inc. announced that it expects to receive $50 million in funding from Hercules Capital, Inc., and other investors Nov 15
Third quarter 2024 earnings released: US$0.43 loss per share (vs US$0.53 loss in 3Q 2023) Nov 07
New major risk - Share price stability Oct 02
Alector, Inc. Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024) Sep 19
Co-Founder recently sold €117k worth of stock Sep 06 See more updates
Alector, Inc. Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’S Disease and Provides Business Update Nov 26 Alector, Inc. announced that it expects to receive $50 million in funding from Hercules Capital, Inc., and other investors Nov 15
Third quarter 2024 earnings released: US$0.43 loss per share (vs US$0.53 loss in 3Q 2023) Nov 07
New major risk - Share price stability Oct 02
Alector, Inc. Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024) Sep 19
Co-Founder recently sold €117k worth of stock Sep 06
Board Member recently sold €206k worth of stock Aug 25
New major risk - Revenue and earnings growth Aug 09
Second quarter 2024 earnings released: US$0.40 loss per share (vs US$0.016 profit in 2Q 2023) Aug 08
Alector, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Aug 01
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®) Jul 29
Co-Founder recently sold €111k worth of stock Jun 09
Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024 May 10
First quarter 2024 earnings released: US$0.39 loss per share (vs US$0.55 loss in 1Q 2023) May 09
Alector, Inc., Annual General Meeting, Jun 12, 2024 Apr 28
Co-Founder recently sold €120k worth of stock Mar 07
Alector, Inc. Provides Revenue Guidance for the Year Ending 2024 Feb 29
Full year 2023 earnings released: US$1.56 loss per share (vs US$1.62 loss in FY 2022) Feb 28
Alector, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024 Feb 21
Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’S Disease Feb 09 Alector, Inc. has completed a Follow-on Equity Offering in the amount of $71.413049 million. Jan 19
New minor risk - Shareholder dilution Jan 18 Alector, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.
Insufficient new directors Dec 15
Insufficient new directors Dec 15
New major risk - Revenue and earnings growth Dec 12
Co-Founder recently sold €122k worth of stock Dec 08 Alector, Inc. has filed a Follow-on Equity Offering in the amount of $125 million. Nov 09
Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023 Nov 08
Third quarter 2023 earnings released: US$0.53 loss per share (vs US$0.56 loss in 3Q 2022) Nov 08
Alector, Inc. Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to Progranulin Gene Mutation (FTD-GRN) Oct 28
Alector, Inc. Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002 Sep 08
Second quarter 2023 earnings released: EPS: US$0.016 (vs US$0.12 in 2Q 2022) Aug 06
Alector, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 29
First quarter 2023 earnings released: US$0.55 loss per share (vs US$0.54 loss in 1Q 2022) May 07
Alector, Inc. Provides Revenue Guidance for the Year 2023 May 05
Co-Founder recently sold €89k worth of stock Mar 25
Key Executive recently sold €79k worth of stock Mar 06
Full year 2022 earnings released: US$1.62 loss per share (vs US$0.45 loss in FY 2021) Mar 02
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.56 loss per share (vs US$1.56 profit in 3Q 2021) Nov 10
Alector, Inc. Announces Promotion of Clare Hunt to Chief People Officer Oct 14
Alector, Inc. Announces Resignation of Robert King as Chief Development Officer Oct 07
Alector, Inc. Initiates Phase 1 Clinical Trial of Al044 for the Treatment of Alzheimer’s Disease Sep 13
Second quarter 2022 earnings released: EPS: US$0.12 (vs US$0.69 loss in 2Q 2021) Aug 05
Alector, Inc Developing AL003 to Treat Patients with Alzheimer's Disease as One of Two Programs Pursuant to the Co-Development and Option Agreement Jul 09
First quarter 2022 earnings released: US$0.54 loss per share (vs US$0.66 loss in 1Q 2021) May 07
Insufficient new directors Apr 27
Alector, Inc. Announces Appointment of Gary Romano as Chief Medical Officer Mar 30
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 27
Forecast breakeven date pushed back to 2023 Feb 26
Alector, Inc. Announces Executive Changes Feb 08
Forecast breakeven date pushed back to 2022 Dec 31
Third quarter 2021 earnings released: EPS US$1.56 (vs US$0.67 loss in 3Q 2020) Nov 06
Insufficient new directors Nov 02
Alector Announces First Participant Dosed in Phase 2 Study Evaluating Al001 in Amyotrophic Lateral Sclerosis (Als) Sep 10
Forecast to breakeven in 2021 Aug 12
Forecast to breakeven in 2023 Aug 05
Second quarter 2021 earnings released: US$0.69 loss per share (vs US$0.58 loss in 2Q 2020) Aug 04
First quarter 2021 earnings released: US$0.66 loss per share (vs US$0.54 loss in 1Q 2020) May 07
Advisor has left the company May 05
Revenue misses expectations Feb 28
Full year 2020 earnings released: US$2.45 loss per share (vs US$1.71 loss in FY 2019) Feb 28
New 90-day high: €16.40 Feb 04
Alector, Inc. Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s Disease Jan 28
Alector, Inc. Announces Executive Changes Jan 22
New 90-day high: €13.70 Jan 19
New 90-day high: €12.40 Dec 10
Revenue misses expectations Nov 11
Third quarter 2020 earnings released: US$0.67 loss per share Nov 11
New 90-day low: €8.50 Oct 10
New 90-day low: €9.45 Sep 25
New 90-day low - €10.70 Aug 20
First half earnings released Aug 12
New 90-day low - €14.50 Jul 30 Shareholder Returns 0Z2 DE Biotechs DE Market 7D -12.8% -2.9% -2.6% 1Y -76.4% -14.7% 6.9%
See full shareholder returns
Return vs Market: 0Z2 underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is 0Z2's price volatile compared to industry and market? 0Z2 volatility 0Z2 Average Weekly Movement 15.7% Biotechs Industry Average Movement 6.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 0Z2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0Z2's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer’s disease.
Show more Alector, Inc. Fundamentals Summary How do Alector's earnings and revenue compare to its market cap? 0Z2 fundamental statistics Market cap €174.58m Earnings (TTM ) -€151.82m Revenue (TTM ) €58.95m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0Z2 income statement (TTM ) Revenue US$61.51m Cost of Revenue US$187.20m Gross Profit -US$125.69m Other Expenses US$32.72m Earnings -US$158.41m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.62 Gross Margin -204.35% Net Profit Margin -257.54% Debt/Equity Ratio 0%
How did 0Z2 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 22:40 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Alector, Inc. is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Leon Wang Barclays Carter Gould Barclays Gregory Harrison BofA Global Research
Show 13 more analysts 
